GSK1838705A

SIGMA/SML0995 - ≥98% (HPLC)

Synonym: 2-[[2-[[1-[(Dimethylamino)ethanoyl]-5-(methyloxy)-2,3-dihydro-1H-indol-6-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-6-fluoro-N-methylbenzamide; 2-[[2-[[1-[2-(Dimethylamino)acetyl]-2,3-dihydro-5-methoxy-1H-indol-6-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-6-fluoro-N-methyl-benzamide

CAS Number: 1116235-97-2
Empirical Formula (Hill Notation): C₂₇H₂₉FN₈O₃
Molecular Weight: 532.57
Linear Formula: C₂₇H₂₉FN₈O₃
Product Type: Chemical

Catalog Number	PKG Qty.	Price


45-SML0995-5MG	5 mg	$131.00 1/EA	Add To Favorites
45-SML0995-25MG	25 mg	$523.00 1/EA	Add To Favorites

This image is provided for informative purposes only and does not represent an actual product label. It should not be used as a substitute for official product labeling.

Properties
Descriptions
Safety Info.
Basic Data

assay	≥98% (HPLC)
color	white to light brown
form	powder
InChI	1S/C27H29FN8O3/c1-29-26(38)23-17(28)6-5-7-18(23)31-25-16-8-10-30-24(16)33-27(34-25)32-19-13-20-15(12-21(19)39-4)9-11-36(20)22(37)14-35(2)3/h5-8,10,12-13H,9,11,14H2,1-4H3,(H,29,38)(H3,30,31,32,33,34)
InChI key	HZTYDQRUAWIZRE-UHFFFAOYSA-N
Quality Level	100
SMILES string	Fc1c(c(ccc1)Nc2nc(nc5[nH]ccc52)Nc3cc4c(cc3OC)CCN4C(=O)CN(C)C)C(=O)NC
solubility	DMSO: 20 mg/mL, clear
storage temp.	−20°C

Application:	GSK1838705A has been used as an insulin receptor inhibitor in Roswell Park memorial institute medium (RPMI) 1640 medium for inhibitor experiments, to prove that the induction of interleukin-1 β (IL-1β) is dependent on insulin receptor signaling.
Biochem/physiol Actions:	GSK1838705A can be used to treat prostate cancer (PC). It is capable of decreasing the viability of docetaxel-sensitive and docetaxel-resistant prostate cancer cells. GSK1838705A can stimulate apoptosis of PC-3R cells. It is an alternative therapeutic option for crizotinib-resistant anaplastic large cell lymphoma (ALCL).
Biochem/physiol Actions:	GSK1838705A is a cell penetrant anti-tumor agent that potently inhibits the insulin-like growth factor-I receptors (IGF-IR), insulin receptors (IR) and anaplastic lymphoma kinase (ALK).
Biochem/physiol Actions:	GSK1838705A is a cell penetrant anti-tumor agent that potently inhibits the insulin-like growth factor-I receptors (IGF-IR), insulin receptors (IR) and anaplastic lymphoma kinase (ALK). GSK1838705A potently inhibits cell proliferation of multiple solid and hematologic cancers and retards the growth of human tumor xenografts. GSK1838705A does not significantly affect other kinases. GSK1838705A has minimal effects on glucose homeostasis in mice.

RIDADR	NONH for all modes of transport
WGK Germany	WGK 3
Flash Point(F)	Not applicable
Flash Point(C)	Not applicable

Purity	≥98% (HPLC)
Storage Temp.	−20°C
UNSPSC	12352200

To Order From a Quote